

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

well written review article. Challenges in future would be mode of delivery, source of FMT, diversity of microbiome. I will recommend the authors to add a paragraph on informed consent as it is still considered a part of valid IRB across the US hospital centers. Also, a paragraph about adverse events of FMT including severe cases of sepsis with gram negative bacteremia.

Reply: We have supplemented adverse events of FMT in the text. The issue of informed consent is relatively tricky, and different countries have different levels. We are also actively reviewing a large number of literature to improve and supplement it.



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The role of intestinal microbiota In a number of pathological conditions, including Inflammatory bowel diseases, is increasing. Fecal microbiota transplantation is emerging as an important therapeutic tool in conditions such as infection by C difficile and other gastrointestinal diseases. Therefore this review article is of great interest to the readers of the Journal. It is well written, highly informative and updated and, as such, is worth being published in the Journal. I have a minor suggestion to the Authors which might help improve the manuscript COMMENT: the Authors may want to give some more details on the mechanisms whereby alteration of intestinal microbiota may interfere with the integrity of intestinal mucosa. To this purpose the Authors may want to quote an discuss the review article by De Musis C et al (Inflammatory bowel diseases: the role of intestinal microbiota, Curr Pharm Des 2020; 26:2951-2961).

Reply: Thank you very much. We will work harder to improve the text.